Back to top
more

Colfax Corporation (CFX)

(Delayed Data from NYSE)

$30.27 USD

30.27
2,700,022

+0.52 (1.75%)

Updated May 3, 2019 04:02 PM ET

After-Market: $30.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Colfax (CFX) Moves 5.8% Higher: Will This Strength Last?

by Zacks Equity Research

Colfax (CFX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Colfax (CFX) Q4 Earnings Top Estimates, 2021 View Impressive

by Zacks Equity Research

Colfax's (CFX) Q4 earnings decrease year over year, reflecting the impacts of weak sales generation and a decline in margins. For 2021, it anticipates y/y revenue and earnings growth.

Colfax (CFX) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Colfax (CFX) delivered earnings and revenue surprises of 4.08% and -0.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Colfax's (CFX) Unit Closes Buyout of Trilliant Surgical

by Zacks Equity Research

Colfax (CFX) arm DJO closes buyout of Trilliant Surgical, which will boost its product offerings and growth prospects in the foot and ankle surgery market.

Madhurima Das headshot

5 Industrial Stocks Near 52-Week Highs That Can Scale Higher

by Madhurima Das

The industrial sector is gearing up for growth in 2021. ParkerHannifin (PH), Fortune Brands (FBHS), Reliance Steel (RS), Rexnord (RXN) and Colfax (CFX) are performing well and are set to grow.

Is Colfax (CFX) a Profitable Stock for Value Investors Now?

by Zacks Equity Research

Let's see if Colfax (CFX) stock is a good choice for value-oriented investors right now from multiple angles.

Is Colfax (CFX) a Profitable Stock for Value Investors Now?

by Zacks Equity Research

Let's see if Colfax (CFX) stock is a good choice for value-oriented investors right now from multiple angles.

Colfax (CFX) Arm's LiteCure Buyout to Boost Product Portfolio

by Zacks Equity Research

Colfax's (CFX) acquisition of LiteCure will create strong growth opportunities for DJO in the physical therapy and rehabilitation market.

Colfax (CFX) to Gain From Products & Buyouts Amid Pandemic Woes

by Zacks Equity Research

Colfax's (CFX) product launches, exposure in multiple markets and gains from buyouts to prove beneficial. However, the pandemic-led challenges and lower selling days remain concerning for Q4.

Colfax (CFX) Arm DJO Acquires Stryker's Extremity Products

by Zacks Equity Research

Colfax (CFX) arm DJO closes buyout of products/system related to ankle replacement and finger arthroplasty from Stryker, which will boost its product offerings in the reconstructive products space.

Colfax (CFX) Q3 Earnings Beat Estimates, Fall Y/Y on Sales

by Zacks Equity Research

Colfax's (CFX) Q3 earnings reflect the impacts of poor product demand due to the pandemic, forex woes and a fall in margin. For Q4, it predicts a sequential rise in sales and earnings.

Colfax (CFX) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Colfax (CFX) delivered earnings and revenue surprises of 2.50% and 6.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Colfax (CFX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Parker-Hannifin Gains From Acquisitions Amid Pandemic Scare

by Zacks Equity Research

Parker-Hannifin (PH) is likely to benefit from strength across its end markets and acquired assets. The coronavirus outbreak-led market downturn and high debt level pose concerns.

Reasons Why it is Worth Investing in Colfax (CFX) Stock Now

by Zacks Equity Research

Colfax (CFX) to benefit from growth opportunities in the Fabrication Technology and Medical Technology segments. Also, business in multiple end markets and cost-reduction actions are other tailwinds.

EnPro (NPO) Shares Gain 20% in 3 Months: What's Driving It?

by Zacks Equity Research

EnPro (NPO) benefits from its focus on restructuring portfolio, expertise in material science, cost-management actions and other growth-oriented initiatives.

Graco (GGG) Shares Gain 29% in 3 Months: What's Driving It?

by Zacks Equity Research

Graco (GGG), with a 29% rise in shares in the past three months, benefits from a solid product portfolio, product launches and the reviving U.S. manufacturing activities.

IDEX's Diversified Businesses & Buyouts to Aid Amid Pandemic

by Zacks Equity Research

IDEX's (IEX) diversified product offerings, presence in multiple markets, acquired assets and cost-saving measures might aid performances in the quarters ahead. The pandemic-led headwinds persist.

Colfax's Products & Cost-Saving Actions to Aid Amid Pandemic

by Zacks Equity Research

Colfax's (CFX) focus on innovation and product launches along with cost-saving measures might aid performances in the quarters ahead. Adversities caused by the pandemic and high debts are concerning.

Colfax (CFX) Up 6.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Colfax (CFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Colfax (CFX) Tops Q2 Earnings Estimates, Gives Impressive View

by Zacks Equity Research

Colfax's (CFX) Q2 results reflect the adverse impacts of the pandemic on product demand and forex woes. It predicts generating sequentially higher profits and positive cash flow in Q3.

Colfax (CFX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Colfax (CFX) delivered earnings and revenue surprises of 50.00% and 2.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Colfax (CFX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cintas (CTAS) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Cintas' (CTAS) fiscal Q4 performance is expected to have gained from an expanded product portfolio and the G&K Services buyout despite the pandemic-led market downturn.

Allegion (ALLE) to Post Q2 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Allegion's (ALLE) Q2 earnings are expected to have gained from strength in residential and non-residential businesses. The pandemic-led market downturn and forex woes might have been dragging.